Proceeds from the financing will be used to progress the company's lead program focused on selective, small-molecule inhibitors of the protein RAD51 for use in oncology, with the goal of entering initial clinical trials in 2019.
Proceeds will also be used to accelerate preclinical development of synthetic lethality therapeutics for autoimmune diseases.
Cyteir Therapeutics discovers and develops novel therapeutics based on the biology of DNA repair and synthetic lethality for the treatment of cancer and autoimmune diseases.
The company's initial approach takes advantage of the "gain-of-function" from DNA damage overload to induce selective self-destruction of cells by targeting disease-induced RAD51 transport.
Mabwell and Qilu Pharmaceutical enter licence agreement for Albipagrastim alfa for Injection
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Biovica secures European patent for biomarker use in immuno-oncology
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Aiforia Technologies launches CE-IVD marked AI solution for breast cancer diagnostics
Stockholders approve proposed merger of TuHURA Biosciences and Kineta
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
Harbour BioMed and Otsuka collaborate on advancing BCMAxCD3 bispecific T-cell engagers
Dizal completes enrolment in sunvozertinib vs. platinum doublet phase III study